| Chimeric antigen receptor T cells are innovative therapies for hematologic malignancies, for which a strict post-marketing monitoring has been recommended. |
| Our disproportionality analyses identified new potential signals, as cardiomyopathies and gastrointestinal perforations for axi-cel, hepatotoxicity and pupil disorders for tisa-cel. |
| Our findings provide insights into different safety profiles for the chimeric antigen receptor T-cell therapies investigated, and into a unified neurotoxicity-cytokine release syndrome. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.